title: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
abstract: OBJECTIVE
  To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," published in 2004.
  
  
  METHODS
  Modified Delphi method with a consensus conference of 55 international experts, several subsequent meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. This process was conducted independently of any industry funding.
  
  
  METHODS
  We used the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system to guide assessment of quality of evidence from high (A) to very low (D) and to determine the strength of recommendations. A strong recommendation (1) indicates that an intervention's desirable effects clearly outweigh its undesirable effects (risk, burden, cost) or clearly do not. Weak recommendations (2) indicate that the tradeoff between desirable and undesirable effects is less clear. The grade of strong or weak is considered of greater clinical importance than a difference in letter level of quality of evidence. In areas without complete agreement, a formal process of resolution was developed and applied. Recommendations are grouped into those directly targeting severe sepsis, recommendations targeting general care of the critically ill patient that are considered high priority in severe sepsis, and pediatric considerations.
  
  
  RESULTS
  Key recommendations, listed by category, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures before antibiotic therapy (1C); imaging studies performed promptly to confirm potential source of infection (1C); administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7-10 days of antibiotic therapy guided by clinical response (1D); source control with attention to the balance of risks and benefits of the chosen method (1C); administration of either crystalloid or colloid fluid resuscitation (1B); fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); vasopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure > or = 65 mm Hg (1C); dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for postoperative patients). In the absence of tissue hypoperfusion, coronary artery disease, or acute hemorrhage, target a hemoglobin of 7-9 g/dL (1B); a low tidal volume (1B) and limitation of inspiratory plateau pressure strategy (1C) for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); application of at least a minimal amount of positive end-expiratory pressure in acute lung injury (1C); head of bed elevation in mechanically ventilated patients unless contraindicated (1B); avoiding routine use of pulmonary artery catheters in ALI/ARDS (1A); to decrease days of mechanical ventilation and ICU length of stay, a conservative fluid strategy for patients with established ALI/ARDS who are not in shock (1C); protocols for weaning and sedation/analgesia (1B); using either intermittent bolus sedation or continuous infusion sedation with daily interruptions or lightening (1B); avoidance of neuromuscular blockers, if at all possible (1B); institution of glycemic control (1B), targeting a blood glucose < 150 mg/dL after initial stabilization (2C); equivalency of continuous veno-veno hemofiltration or intermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1A); use of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limitation of support where appropriate (1D). Recommendations specific to pediatric severe sepsis include greater use of physical examination therapeutic end points (2C); dopamine as the first drug of choice for hypotension (2C); steroids only in children with suspected or proven adrenal insufficiency (2C); and a recommendation against the use of recombinant activated protein C in children (1B).
  
  
  CONCLUSIONS
  There was strong agreement among a large cohort of international experts regarding many level 1 recommendations for the best current care of patients with severe sepsis. Evidenced-based recommendations regarding the acute management of sepsis and septic shock are the first step toward improved outcomes for this important group of critically ill patients.
authors.affiliation: Cooper University Hospital, Camden, NJ, USA. Dellinger-Phil@CooperHealth.edu
authors.forename: R Phillip
authors.initials: RP
authors.lastname: Dellinger
authors.forename: Mitchell M
authors.initials: MM
authors.lastname: Levy
authors.forename: Jean M
authors.initials: JM
authors.lastname: Carlet
authors.forename: Julian
authors.initials: J
authors.lastname: Bion
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Parker
authors.forename: Roman
authors.initials: R
authors.lastname: Jaeschke
authors.forename: Konrad
authors.initials: K
authors.lastname: Reinhart
authors.forename: Derek C
authors.initials: DC
authors.lastname: Angus
authors.forename: Christian
authors.initials: C
authors.lastname: Brun-Buisson
authors.forename: Richard
authors.initials: R
authors.lastname: Beale
authors.forename: Thierry
authors.initials: T
authors.lastname: Calandra
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Dhainaut
authors.forename: Herwig
authors.initials: H
authors.lastname: Gerlach
authors.forename: Maurene
authors.initials: M
authors.lastname: Harvey
authors.forename: John J
authors.initials: JJ
authors.lastname: Marini
authors.forename: John
authors.initials: J
authors.lastname: Marshall
authors.forename: Marco
authors.initials: M
authors.lastname: Ranieri
authors.forename: Graham
authors.initials: G
authors.lastname: Ramsay
authors.forename: Jonathan
authors.initials: J
authors.lastname: Sevransky
authors.forename: B Taylor
authors.initials: BT
authors.lastname: Thompson
authors.forename: Sean
authors.initials: S
authors.lastname: Townsend
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Vender
authors.forename: Janice L
authors.initials: JL
authors.lastname: Zimmerman
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Vincent
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000698:Analgesia / Q000379:methods; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D001803:Blood Transfusion / Q000379:methods; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002648:Child; D016292:Procedural Sedation / Q000379:methods; D003422:Critical Care / Q000379:methods / Q000592:standards*; D003697:Delphi Technique; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D019148:Neuromuscular Blockade / Q000379:methods; D010437:Peptic Ulcer / Q000209:etiology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D017582:Renal Replacement Therapy / Q000379:methods; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000628:therapy; D012151:Resuscitation / Q000379:methods; D018805:Sepsis / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D012772:Shock, Septic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D001639:Bicarbonates; D001786:Blood Glucose; D002316:Cardiotonic Agents; D011486:Protein C; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; C421124:drotrecogin alfa activated